Q3 2023 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2023-11-14 · accession 0001583977-23-000005
$1.71B
Reported value
49
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $464.1M | 27.1% | 8,142,100 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $123.0M | 7.17% | 4,662,530 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $114.1M | 6.66% | 9,923,689 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $77.1M | 4.50% | 2,150,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $76.1M | 4.44% | 2,000,000 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $57.4M | 3.35% | 3,850,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $55.6M | 3.25% | 4,504,764 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $53.3M | 3.11% | 1,056,373 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $49.1M | 2.87% | 3,570,872 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $47.0M | 2.74% | 1,225,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $46.6M | 2.72% | 2,621,422 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $43.8M | 2.56% | 2,879,424 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $33.9M | 1.98% | 665,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $32.8M | 1.91% | 1,101,904 | Common | SOLE |
| 45254E107 | IMRX | IMMUNEERING CORP | $32.3M | 1.88% | 4,204,364 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $28.4M | 1.66% | 1,361,460 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $26.2M | 1.53% | 1,182,263 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $25.6M | 1.49% | 3,200,000 | Common | SOLE |
| 48576A100 | — | KARUNA THERAPEUTICS INC | $23.7M | 1.38% | 140,000 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $21.8M | 1.27% | 1,900,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $21.3M | 1.24% | 10,813,246 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $21.2M | 1.24% | 1,561,696 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $21.1M | 1.23% | 2,625,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $19.5M | 1.14% | 850,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $16.9M | 0.98% | 2,946,887 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $16.6M | 0.97% | 1,216,712 | Common | SOLE |
| 74006W108 | — | PRAXIS PRECISION MEDICINES I | $16.2M | 0.95% | 9,500,000 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $16.2M | 0.94% | 600,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $14.5M | 0.85% | 575,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $14.0M | 0.82% | 700,000 | Common | SOLE |
| 05465P101 | AXNX* | AXONICS INC | $14.0M | 0.82% | 250,000 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $13.1M | 0.76% | 2,353,141 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $11.2M | 0.66% | 1,762,115 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $10.6M | 0.62% | 225,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $9.8M | 0.57% | 1,000,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $9.2M | 0.54% | 450,000 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $6.0M | 0.35% | 593,043 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $5.4M | 0.32% | 325,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $4.6M | 0.27% | 350,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $4.3M | 0.25% | 1,087,807 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $3.6M | 0.21% | 561,600 | Common | SOLE |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $3.3M | 0.19% | 616,786 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $2.9M | 0.17% | 612,079 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $2.1M | 0.12% | 81,963 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $2.0M | 0.12% | 1,181,115 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $1.3M | 0.08% | 92,293 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $913,749 | 0.05% | 392,167 | Common | SOLE |
| 41358P205 | HARPUSD | HARPOON THERAPEUTICS INC | $217,862 | 0.01% | 54,060 | Common | SOLE |
| 68570P200 | — | ORCHARD THERAPEUTICS PLC | $198,383 | 0.01% | 25,664 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.